RxDoctor Payments Data

Nasser Lavaud

Nurse Practitioner · Lantana, FLNPI 1205207883

Payments from drug & device makers

$2,598in general payments, 2019–2025

Across 136 payments — averaging $19.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$572
  • Acadia Pharmaceuticals Inc$525
  • Otsuka America Pharmaceutical, Inc.$392
  • Avanir Pharmaceuticals, Inc.$340
  • Alpha Cognition USA, Inc.$299
  • Teva Pharmaceuticals USA, Inc.$296
  • plus $174 from 4 others

What the payments were for

  • Food & beverage$2,598100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,598 in reported general payments places this provider in the 85th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$231,822
Medicare patients
1,017
Services billed
2,401

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate62$330,012
NuedextaDextromethorphan Hbr/Quinidine85$135,392
Divalproex Sodium163$13,950
VraylarCariprazine Hcl16$10,887
Trazodone Hcl370$8,139
Lorazepam327$4,602
Alprazolam325$4,185
Oxcarbazepine85$3,893
Mirtazapine79$2,956
Sertraline Hcl91$1,964
Divalproex Sodium ErDivalproex Sodium18$1,128
Quetiapine Fumarate38$1,030
Estradiol32$876
Donepezil Hcl43$785
Paroxetine Hcl19$525

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$525$330,01262 claims
Avanir Pharmaceuticals, Inc.Nuedexta$340$135,39285 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Lantana

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →